Today: Today, Brean Capital Initiates Coverage on Recro Pharma Inc. (REPH)

Today, Brean Capital Initiates Coverage on Recro Pharma Inc. (REPH)

Brean Capital began coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research report report published on Monday morning. The firm issued a buy rating and a $21.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Recro Pharma from a hold rating to a sell rating in a research note on Wednesday, June 15th. HC Wainwright reaffirmed a buy rating on shares of Recro Pharma in a research note on Monday, July 18th. Roth Capital assumed coverage on shares of Recro Pharma in a research note on Friday, September 16th. They set a buy rating and a $24.00 price target for the company. Finally, Janney Montgomery Scott assumed coverage on shares of Recro Pharma in a research note on Monday, August 29th. They set a buy rating and a $21.00 price target for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $17.55.

Shares of Recro Pharma (NASDAQ:REPH) opened at 8.16 on Monday. Recro Pharma has a 52 week low of $5.59 and a 52 week high of $12.86. The stock’s market capitalization is $80.53 million. The firm’s 50-day moving average price is $9.19 and its 200 day moving average price is $8.08.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. The firm earned $17.30 million during the quarter, compared to the consensus estimate of $18.70 million. Recro Pharma had a negative return on equity of 52.80% and a negative net margin of 8.70%. Analysts expect that Recro Pharma will post ($3.13) earnings per share for the current year.

In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin acquired 390,000 shares of Recro Pharma stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average price of $7.50 per share, with a total value of $2,925,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 39.30% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Recro Pharma by 0.4% in the second quarter. Vanguard Group Inc. now owns 107,252 shares of the specialty pharmaceutical company’s stock worth $852,000 after buying an additional 400 shares during the period. BlackRock Fund Advisors increased its position in shares of Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock worth $121,000 after buying an additional 4,163 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock worth $397,000 after buying an additional 11,682 shares during the period. Finally, Stonepine Capital Management LLC increased its position in shares of Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock worth $3,408,000 after buying an additional 191,796 shares during the period. 36.38% of the stock is owned by institutional investors.

Recro Pharma Company Profile

Related posts

Leave a Comment